Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Combination therapy in gynecoligcal cancer

Mansoor Mirza • 5 Nov 2019
ESMO 2019
Endometrial Cancer Gynecological Cancer Lenvatinib Pembrolizumab

Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, speaks on the FDA approval of lenvatonib and the future of combination immunotherapy in endometrial cancers. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
8:20
Immune checkpoint inhibitors for endometrial and cervical cancer
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals